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Objective. Fetuin-A has been associated with gestational diabetes mellitus (GDM). We investigated fetuin-A levels during and
after pregnancy in women with GDM. Fetuin-A measurements were performed in 10 women with GDM and 10 age and body
mass index (BMI) matched healthy pregnant women. All women underwent an oral glucose tolerance test (OGTT) in and 3
months after gestation. Results. Fasting fetuin-A correlated with BMI in women with former GDM (r = 0.90, P<0.0001) but
showed no association with parameters of glucose tolerance in women with GDM or post-GDM. GDM featured signiﬁcantly
lower insulin sensitivity and higher insulin and C-peptide secretion proﬁles compared to NGT during pregnancy (P<0.05).
Fasting and postprandial fetuin-A did not diﬀer between groups, neither during nor after pregnancy. Conclusion. Fetuin-A is not
inﬂuencedbyglucosetoleranceduringorafterpregnancyoracuteglucoseelevationsfollowingglucoseingestioninyoungwomen,
but closely relates to BMI early postpartum.
1.Introduction
Fetuin-A is a potent systemic calciﬁcation inhibitor [1]. Be-
side this function fetuin-A has been shown to interact with
insulin receptor tyrosine kinase, thereby inducing insulin
resistanceinrodents[2,3].Incross-sectionalhumanstudies,
fetuin-A has been linked to insulin resistance and metabolic
syndrome [4]. Furthermore fetuin-A has been linked to
incident diabetes mellitus in the Health ABC study [5].
Stefan et al. were able to demonstrate a relation between
fetuin-A and liver fat accumulation in insulin-resistant sub-
jects [6]. In pregnant women fetuin-A levels were shown to
increase with gestational age [7]. Furthermore women with
gestational diabetes (GDM) display higher levels of fetuin-
A compared to normal glucose tolerant counterparts [7].
However, GDM being regarded as pre-type 2 diabetes may
comprise a very heterogeneous group of women of diﬀerent
ethnicity and with varying degree of obesity. Therefore, in-
vestigating fetuin-A behavior in women with GDM may
provide a possibility to further elucidate the role of fetuin-
A in early stages of diabetes mellitus. Therefore we aimed to
investigate the role of acute glucose ingestion during a stand-
ardizedoralglucosetolerancetest(OGTT)onplasmafetuin-
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mal-weight to moderately overweight women with and
without GDM during as well as after partum.2 International Journal of Endocrinology
2. Methods
The study was performed as a case-control study. Women
with GDM were recruited consecutively from the Depart-
mentofObstetricsandGynecologyoftheMedicalUniversity
of Vienna. Those who gave informed consent underwent a
2h oral glucose tolerance test (OGTT). Data from 10 women
withGDMand10womenwithNGTduringpregnancy(28th
week of gestation), matched for age and BMI in a 1:1 ratio,
were analyzed. A second OGTT was performed 10–12 weeks
after delivery. Women with previous ketoacidosis and/or
beta-cell antibodies (GAD, ICA, IA2), severe chronic disease,
kidney or liver disease, and those on chronic medication
of drugs known to inﬂuence carbohydrate metabolism were
excluded.
2.1. OGTT. GDM was diagnosed according to the criteria of
the 4th International. Workshop Conference on GDM [8].
After an overnight fast for at least 12h, blood samples for the
measurement of glucose, insulin, and C-peptide were taken
atbaselineaswellasat30,60,90,and120minafteringestion
of 75g glucose. Fetuin-A levels were measured at fasting as
well as 30, 60, and 120 minutes after glucose load.
2.2. Plasma Metabolites. Plasma levels of fetuin-A were
measured by an enzyme-linked radioimmunoassay (ELISA)
(Biovendor laboratory medicine, Modreci, Czech republic).
Intra-assay coeﬃcients of variation were 3.5% and interassay
coeﬃcient of variation 5.4%. Glucose, insulin, C-peptide,
glutamate oxalacetat transaminase (GOT), glutamat-pyru-
vat-transaminase (GPT), bilirubin, cholinesterase (CHE),
cholesterol, high-density lipoprotein cholesterol (HDL-c),
low-density lipoprotein cholesterol (LDL-c), triglyceride
(TG), and HbA1c were measured using standard kits avail-
able in our central laboratory.
2.3. Data Analysis. The kinetics of glucose, insulin, and
C-peptide during OGTT were analyzed by quantitative
methodstoobtainmetabolicparameters,suchasinsulinsen-
sitivitythroughoralglucoseinsulinsensitivityindex(OGIS),
which describes glucose clearance per unit change of insulin
concentration [9]. Total insulin secretion (TIS) from C-pep-
tide, its suprabasal component (dynamic TIS), and hepatic
insulin extraction (HIE) were obtained with a mathematical
model of insulin/C-peptide interactions [10, 11]. β-Cell
function was described as the ability of the β-cell to adapt
insulin secretion to the prevailing insulin resistance and
was quantiﬁed by the products: OGIS dynamic AUC insulin
(termed disposition index) and OGIS dynamic TIS (termed
adaptation index), where AUC is the area under the insulin
concentration curve during the whole test.
2.4. Statistical Analysis. Comparisons of quantitative vari-
ables among groups were performed using Student’s t-test.
Associations between continuous variables are described by
the Spearman correlation coeﬃcient. Levels of statistical sig-
niﬁcance were set at P<0.05.
3. Results
WomenwithandwithoutGDMwerecomparableintermsof
their medical history. There were also no diﬀerences in bas-
eline as well as 3 months postpartum laboratory parameters
of lipoproteins and liver enzymes (Table 1). During gestation
women with GDM displayed signiﬁcant higher fasting insu-
lin, C-peptide, and AUC of both parameters during OGTT.
OGIS was signiﬁcantly lower in women with GDM com-
pared to those with NGT (Table 1)a n dFigure 1(a).
Three months after delivery, 3 women from the GDM
group had a pathologic glucose tolerance status and the
remaining 7 returned to normal glucose values. Insulin and
C-peptide secretion proﬁles were still higher in women from
the former GDM compared to NGT group but without
reaching statistical signiﬁcance (Table 1). Also OGIS were
still lower in the former GDM group compared to women
with NGT without statistical signiﬁcance (Table 1)a n d
Figure 1(b).
Fasting and postprandial fetuin-A plasma levels did not
diﬀer between women with GDM and NGT during as well as
3 months after pregnancy (Table 1). During pregnancy there
were no correlations between fetuin-A plasma levels and
parameters of insulin resistance and secretion. Three months
after gestation there was signiﬁcant correlation between
fasting fetuin-A and BMI (r = 0.90, P<0.0001) in women
with former GDM (Figure 2). There were no correlations
between fetuin-A plasma concentrations and GOT, GPT, or
bilirubin.
4. Discussion
In the present study we found that fetuin-A plasma levels did
not diﬀer between women with and without GDM even
when measured during as well as after pregnancy. Addition-
ally we found that fetuin-A was not aﬀected by acute glucose
ingestion both during as well as after gestation. Interestingly
we found that fetuin-A did not correlate with parameters
of obesity and insulin resistance during pregnancy. However
three months after gestation there was a strong correlation
between fasting fetuin-A and BMI in those from the former
GDM group. One study investigated the relation between
fetuin-A levels and parameters of insulin resistance during
normal pregnancy and in women with GDM [7]. In that
study fetuin-A levels increased during the course of uncom-
plicated gestation [7]. Additionally women with GDM had
signiﬁcantly higher fetuin-A levels compared to healthy
pregnant women [7]. Furthermore they found a signiﬁcant
correlationbetweenfetuin-Alevelsandparametersofinsulin
resistance such as fasting C-peptide and C-peptide to glucose
ratio [7]. However the diﬀerences between those results and
our ﬁndings could be explained by study design and meth-
ods. GDM women in the study of Kabaly et al. were more
obese than subjects in our investigation. Furthermore we
used more sophisticated methods to measure insulin resis-
tance. Under experimental conditions high glucose levels
were able to activate fetuin-A gene promoter [12]. This acti-
vation was dose dependent and occurred after at least 3International Journal of Endocrinology 3
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Figure 1:(a)BoxplotofOGISlevel(mLmin−1m−2)inwomenwithandwithoutgestationaldiabetesmellitusduringpregnancy(P = 0.001).
(b) Boxplot of OGIS level (mL min−1m−2) in women with and without gestational diabetes mellitus 3 months after delivery (P = 0.06).
Table 1: Patient’s characteristics and laboratory parameters.
Variable Third trimester of gestation P-Value Three months postpartum P Value
NGT (n = 10) GDM (n = 10) NGT (n = 10) GDM (n = 10)
BMI (Kg/m2)2 7 .3 ±1.32 8 .9 ±1.31 0.4 26.5 ±1.58 27.9 ±1.30 0.5
Age (years) 30.4 ±1.73 2 ±2.30 . 5 — — —
Parity 1.1 ±0.42 ±10 . 4 — — —
Systolic blood pressure (mmHg) 116.5 ±4.2 110 ±4.1 0.2 117.6 ±2.9 106.4 ±4.40 . 0 5
Diastolic blood pressure (mmHg) 71.5 ±2.56 7 .7 ±20 . 2 7 3 .1 ±2.46 5 ±2.60 . 0 4
Total cholesterol (mg/dL) 277.1 ±16.4 227.2 ±11.6 0.02 204.5 ±15.2 203 ±10.20 . 9
LDL cholesterol (mg/dL) 159 ±14.8 115 ±9.1 0.02 129.5 ±13 118.4 ±6.80 . 4
HDL cholesterol (mg/dL) 75.6 ±21.36 9 .9 ±3.70 . 4 6 4 .7 ±66 1 .6 ±4.50 . 6
Triglycerides (mg/dL) 197.1 ±20.2 207 ±24.90 . 7 8 1 ±7.5 116.3 ±18.70 . 0 9
HbA1c (%) 4.9 ± 0.11 4.9 ±0.14 0.9 5.2 ±0.15 .3 ±0.08 0.5
Cholinesterase () 5.31 ±0.71 5.23 ±1.39 0.6 7.07 ±0.77 .76 ±1.48 0.1
Bilirubin () 0.33 ±0.13 0.37 ±0.14 0.5 0.7 ±0.42 0.48 ±0.16 0.1
GOT (U/L) 21.6 ±5.12 0 .1 ±3.90 . 82 6 .3 ±7.52 6 .3 ±8.90 . 2
GPT (U/L) 15.8 ±6.11 7 .1 ±7.40 . 42 7 ±13.74 0 .1 ±23.30 . 9
hs-CRP (mg/dL) 0.43 ±0.05 2.15 ±1.75 0.3 0.29 ±0.07 0.21 ±0.07 0.5
Fasting glucose (mg/dL) 80.3 ±2.38 8 .1 ±2.6 0.039 82.4 ±2.99 2 .4 ±3.60 . 0 4
1-hour postload glucose (mg/dL) 135.6 ±7.2 186.1 ±11.5 0.002 105.3 ±8.6 114.1 ±13.40 . 6
Fasting insulin secretion (pmol/L) 12.2 ±1.61 6 .0 ±1.81 0.1 7.8 ±1.41 1 .3 ±2.30 . 2
OGIS 434.05 ±12 341.51 ±19.35 0.001 476.79 ±30.23 408.19 ±18.72 0.06
Disposition index (nmol/m3)3 .87 ±0.44 5.15 ±0.50 0.07 2.49 ±0.43 3.57 ±0.31 0.059
AUC-glucose (mmol/L/min.) 14.21 ±0.54 19.28 ±0.73 0.0001 14.17 ±0.89 17.26 ±1.26 0.1
AUC-insulin (nmol/L/min.) 8.93 ±0.98 15.7 ±2.01 0.007 5.41 ±1.08 9.11 ±1.15 0.46
AUC-C-peptide (nmol/L/min.) 1016.7 ±44.9 1441.3 ±137.9 0.009 777.5 ±98.9 1131.4 ±156.30 . 1
Fasting fetuin-A (ng/mL) 497.5 ±64.3 580 ±46.4 0.8 560.38 ±69.3 571.4 ±80.40 . 8
30-min. after load fetuin-A (ng/mL) 453.9 ±29.8 549.3 ±50 0.5 569.4 ±86.1 571.3 ±87.20 . 5
60-min. after load fetuin-A (ng/mL) 581 ±43.2 513 ±42.1 0.7 577.5 ±114.1 542.7 ±43.80 . 7
120-min. after load fetuin-A (ng/mL) 524.5 ±39.9 539.6 ±33 0.1 414.8 ±48.6 552 ±47.60 . 14 International Journal of Endocrinology
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Figure 2: Scatter diagram of the correlation between fasting post-
partum fetuin-A (ng/mL) and body mass index (BMI) (Kg/m2)i n
women with history of gestational diabetes mellitus (r = 0.90, P<
0.0001).
hours of incubation [12]. In our study during OGTT fetuin-
A plasma levels remained unchanged. We could not exclude
a late elevation of fetuin-A after OGTT. Further studies with
longer fetuin-A collection time points during OGTT or in-
travenous glucose tolerance test are needed to further in-
vestigate the inﬂuence of glucose per se on fetuin-A plasma
concentrations.
However,thefactthatevenchronichyperglycemialinked
to GDM did not alter fetuin-A levels argues against a prom-
inent eﬀect of glucose ﬂuctuations/elevation on fetuin-A
release. Fetuin-A has been linked to obesity in a study per-
formed in patients with morbid obesity [13]. In that study,
fetuin-A levels decreased after weight loss due to gastric by-
pass surgery [13]. Another study investigated the relation
between fetuin-A with parameters of insulin resistance and
fatty liver [14]. In that study obese children with and with-
out nonalcoholic fatty liver (NAFL) were compared. The au-
thors found a relation between fetuin-A and NAFL as well as
a reduction in fetuin-A after weight loss [14]. In our study
we did not investigate the presence of NAFL by ultrasound
as recommended. Despite this there were no diﬀerences in
hepatic transaminases as well as cholinesterase between
women with and without GDM neither in nor after preg-
nancy.Additionallywefoundno correlationof fetuin-Awith
those liver enzymes (data not presented). Women in our
study were only of moderate obesity as compared to children
from the investigation of Reinher and Roth [14]. Based on
our results and in light of previous ﬁndings, it appears that
fetuin-A could be the link between fatty liver disease and
metabolic syndrome. Further investigations in subjects with
obesity with and without NAFL should be performed to ﬁ-
nallyevidencealinkbetweenfattyliverdisease,fetuin-A,and
insulin resistance.
4.1.StudyLimitations. First,asweexaminedasmallcohortit
is diﬃcult to translate our ﬁndings to the general GDM pop-
ulation.Secondthesubjectsinvestigatedwereyoungfemales,
whichwerebesides havingGDMhealthy.Alsothe meanBMI
of our GDM patients was lower than that of the subjects
investigatedbyKalabayetal.[7].Thirdwedidnotinvestigate
the presence of NAFL by ultrasound examination.
5. Conclusion
Our preliminary study suggests that fetuin-A does not relate
to parameters of insulin sensitivity or metabolic control and
doesnotseemtoplayaroleinthepathogenesisofGDM.Fur-
thermore acute glucose changes during an OGTT do not af-
fect fetuin-A plasma concentrations both during and after
pregnancy. However preexisting overweight, which may be
masked by pregnancy, related changes in body weight or
weight retention after pregnancy may have a strong impact
on fetuin-A release.
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